2017-000559-26: A multicentric, international study in order to compare the effectiveness of fingolimod versus dimethyl-fumarate on patients with Multiple Sclerosis. Studio multicentrico, internazionale volto a confrontare l'efficacia di fingolimod e dimetil-fumarato in pazienti con Sclerosi Multipla |
|
|
| Ongoing | 4 | 1360 | Europe | Capsule, hard, Gastro-resistant capsule, hard, GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE, TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE | FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA, Patient-Centered Outcomes Research Institute | relapsing-remitting multiple sclerosis sclerosi multipla recidivante-remittente, multiple sclerosis sclerosi multipla, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05658484: A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China |
|
|
| Active, not recruiting | 4 | 60 | RoW | Dimethyl fumarate, Tecfidera, DMF, BG00012 | Biogen | Multiple Sclerosis | 04/25 | 04/25 | | |
